Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Diabetes drug heart risk reviewed

  • Comment

A controversial diabetes drug treatment will be reviewed amid concerns that it is linked to an increased risk of heart problems and stroke, a European health authority has said.

Avandia, also known as rosiglitazone, will be subject to scrutiny by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) later this month following suggestions that the drug, commonly used by Type 2 diabetes patients, could be putting users at a higher risk of developing potentially fatal heart problems.

The GlaxoSmithKline-developed treatment will also be put under the spotlight by the US Food and Drug Administration (FDA) this week following the publication of a study last month, which reportedly exposed the risk the drug posed, claiming it was more dangerous than a rival treatment, Actos.

Dr David Graham, lead author of the study and a scientist for the FDA, said as many as 100,000 heart attacks, strokes, deaths and cases of heart failure may have been directly caused by Avandia since 1999 and called for it to be banned.

However, the drug’s manufacturer has defended the use of Avandia, saying the treatment has already undergone extensive testing over its safety and efficacy.

Dr Tony Hoos, European medical director for GlaxoSmithKline (GSK), said: “GSK is fully committed to patient safety and believes that rosiglitazone is an important treatment option for appropriate Type 2 diabetes patients.

“It is one of the most extensively researched diabetes medicines and has been studied in more than 50,000 patients.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs